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G-protein-coupled receptors (GPCR) constitute one of the
largest families of cell surface proteins. Not only do they
regulate, after activation by hormones and neurotransmit-
ters, a considerable part of the physiological processes in
the body, but they also represent a major class of drug
targets and thus play an increasingly important role in
medicine. Indeed, more than 30 % of the clinically mar-
keted drugs do act through GPCR and are therapeutically
successful in a large spectrum of human diseases. It is,
therefore, evident that increasing information is needed on
the expression and precise distribution of the GPCR, par-
ticularly in normal and diseased human tissues. The density
of GPCR is usually considerably lower than that of other
cellular parameters, such as that for hormones for instance,
sometimes challenging their detection with current
methods.
Human tissue samples are complex as they usually
include many distinct cell types and compartments (epi-
thelial cells, endocrine cells, nerves, vessels, immune cells,
etc.,). Therefore, it is mandatory to use morphological
methods for an accurate identification of the cell types that
do indeed express the GPCR. Various methods exist to
measure and localize these receptors morphologically,
including, next to receptor mRNA detection with in situ
hybridization, the receptor protein localization with in vitro
radioligand binding using receptor autoradiography (ARG;
gold standard), or immunohistochemistry (IHC) with ade-
quate antibodies. IHC has become very popular because it
is an easy-to-perform morphological method with excellent
resolution and other advantages: Only formalin-fixed tis-
sues are needed, instead of fresh-frozen material, and the
number of available commercial and non-commercial
antibodies is rapidly increasing. The consequence is a
plethora of papers describing IHC findings for GPCR in
human tissues. Unfortunately, several of these published
papers show often questionable data due to the use of
poorly validated antibodies and/or protocols [1–4]. If we do
not want to be overwhelmed by poorly relevant publica-
tions on GPCR-IHC in the near future and by further
controversial discussions in the IHC literature, it is urgent
to react and correct this unsatisfactory tendency. It will be
crucial for scientific journals that regularly publish IHC
studies to introduce recommendations or even clear rules
which would have to be strictly followed by authors, who
otherwise would incur the risk that the submitted paper will
not be evaluated. This initiative has recently been taken by
Endocrinology [5]. But it is evident that the adherence to
such a strategy by all journals reporting IHC data would be
beneficial. Valuable in this regard is also a set of recom-
mendations for the validation of IHC assays in diagnostic
settings that have recently been published by the College of
American Pathologists [6].
What is needed, at first, is a rather basic information,
namely a full description of the antibody characteristics
(antibody name, manufacturer, code number, antigen
sequence if known, species raised in, monoclonal/poly-
clonal, clone designation if applicable, lot number for
polyclonal antibodies). It should further be confirmed that
the antibody was tested successfully in cell lines expressing
the receptor while negative controls in cell lines devoid of
receptors and/or in wild type/knock-out mice should also
be provided [1, 2]. Preferably, such data should be avail-
able for both fresh frozen and corresponding formalin-fixed
materials.
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This preliminary validation of a GPCR antibody does
not warrant its specificity in human tissues. The antibody
needs further to be tested in human tissues as follows:
1 One should take care to identify and use adequate
control tissues—as far as they are known—for the
antibody to be validated, i.e., choose positive controls
containing a known established human target tissue
expressing the receptor of interest. Adjacent non-target
tissue should clearly not react, i.e., ‘‘stain negatively.’’
Antigen pre-absorption tests, such as negative controls
with an excess of antigenic peptide (if available)
should also be provided in adjacent sections of the
same tissue samples. Various antigen retrieval methods
as well as different antibody concentrations should be
applied in initial testing. The results should be
carefully evaluated to obtain an optimal protocol.
Once established, any further tests should strictly
adhere to this protocol. Precaution should be taken
with pancreatic islets when they are used as positive
controls for validation of hormone receptors—as
commercial providers often do—because the islets
have been shown to be occasionally ‘‘immunostained’’
non-specifically [7].
2 One should carefully check the cellular localization of
the immunohistochemical reaction product: by defini-
tion, GPCR are cell surface receptors with seven
transmembrane spanning domains. Therefore, under
normal conditions, we expect to see an immunoreac-
tivity localized at the cell membrane. This is at
difference with other receptor families located per
definition in the cytoplasm and/or in the nucleus, such
as the androgen receptors [8]. For GPCR, therefore, a
diffuse cytoplasmic IHC staining is a doubtful and
most likely non-specific result which is often, errone-
ously, interpreted as specific staining of internalized
receptors. Surely, GPCR can be internalized. Internal-
ization is even part of the physiological mechanism of
action for many GPCR; a specific condition necessary
for this phenomenon to occur is usually an acute
receptor stimulation by agonist treatment. It should be
understood that internalized receptors have a very
particular intracellular distribution, as they are usually
internalized in circumscript endosomes; thus, they are
not diffusely distributed in the cytoplasm [9, 10]. To
precisely evaluate the cellular localization of receptors,
an illustration at high magnification is, therefore,
required. Often authors do not take advantage of the
high resolution of IHC but rather prefer to publish
overview pictures of low magnification that sometimes
mask a poor quality of the immunostaining.
3 One should provide a western blot for the antibody
used in the same human tissues that were found IHC
positive. Such a blot should confirm the identity of the
receptor detected by IHC by showing a single specific
band of the expected molecular weight.
4 One should compare the IHC-based data with data
obtained by use of another morphological receptor-
measuring method (ARG; in situ hybridization) in the
same samples. While of fundamental importance, such
a specificity test, of course, involves considerable
additional work [11] and is, therefore, often omitted.
5 Ideally, one should compare the obtained GPCR-IHC
data with the localization of the same GPCR using
another antibody recognizing a different epitope of the
receptor when such a well-validated antibody is
available.
6 It is true for every IHC study that an optimal formalin-
fixation of the human tissue samples, according to the
standard rules of surgical pathology, is mandatory [6].
Putting the above-mentioned tests into practice will
likely prevent controversies and reduce experimental dis-
crepancies. Otherwise, unnecessary repeats and reports of
IHC experiments with no clear conclusion will be the
consequence, as recently shown by examples in the field of
receptors for somatostatin and GLP1 [1, 2, 12, 13].
Implementation of the above-mentioned tests would,
therefore, not only considerably add to the quality of
published IHC papers, but also help in reproducing
important new data and permitting science to progress on a
safer track.
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